Back to Report Store Home

Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth

  • Published: Oct-2012
  • Report Code: GBIHC255MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Biopharmaceutical Manufacturing in India, China and South Korea - Introduction

2.1 Introduction

3 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of the Biopharmaceutical Industry

3.1 Definition and Objective Analysis of Newly Approved Biopharmaceuticals

3.2 Collective Analysis of Biopharmaceuticals Approved in 2010 and 2011

3.3 Current Scenario in Biopharmaceutical Manufacturing

3.4 Biopharmaceutical Manufacturing

3.5 Factors Driving Outsourcing to India, China and South Korea

3.5.1 Comparative Cost Analysis between In-House Biopharmaceutical Production Versus Contract Manufacturing Organizations

3.6 Growth Drivers for Contract Research and Manufacturing Services

3.7 Contract Manufacturing Benefits

3.8 Operating Cost Analysis in Biopharmaceutical Manufacturing

3.8.1 Labor Cost Analysis

3.8.2 Investment Cost Analysis

3.8.3 Standard Operating Costs

3.9 Cost and Timeline Analysis for Therapeutic Monoclonal Antibody Product Development

3.10 Manufacturing Equipment Trends

3.11 Comparative Analysis of New and Old Equipment

3.12 Consolidation in Pharmaceutical Industry has Resulted in Idle Production Lines

3.13 Biosimilars in Asia

3.14 CMOs to Benefit by Expanding Operations in Biopharmaceutical Manufacturing

3.15 Trends Witnessed in Biopharmaceutical Manufacturing

3.15.1 Single-Use Bioprocessing and Microbial Technologies to Dominate Biopharmaceutical Manufacturing

3.15.2 Biopharmaceutical R&D and Manufacturing Outsourcing to Rise

3.15.3 Market for Biopharmaceuticals to Rise at Brisk Rate

3.15.4 Introduction of Biosimilars to Multiply Biopharmaceutical Manufacturers

3.15.5 R&D Spend in Biopharmaceuticals Insulated from Economic Downturn

3.15.6 Downstream Processing Technologies Acting as Bottleneck in Biopharmaceutical Manufacturing

3.16 Preferred Biopharmaceutical Contract Pricing Model

3.17 Contract Manufacturing Partnerships

3.18 Comparative Analysis of India, China and South Korea with Reference to Government Initiatives, Investment and Skills

4 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical Manufacturing in India

4.1 Augmentation Potential of Biopharmaceuticals in India

4.1.1 Stem Cells

4.1.2 Biosimilars

4.1.3 Vaccines

4.2 Biopharmaceutical Revenues in India

4.3 Drivers and Barriers for Biopharmaceutical Manufacturing in India

4.4 Proposals to the Government for Promoting Biopharmaceutical Manufacturing

4.5 Pharmaceutical Cluster Development in India

4.6 Regulatory Overview for Biopharmaceuticals in India

4.7 Competitive Landscape

4.7.1 Biocon Ltd.

4.7.2 Serum Institute of India Ltd.

4.7.3 Panacea Biotec Ltd

4.7.4 Dr. Reddy’s

4.7.5 Cipla

4.7.6 Lupin

5 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical Manufacturing in China

5.1 Market Size for Chinese Biopharmaceuticals

5.2 Economic Impact of Biopharmaceuticals Approved in China

5.3 Biopharmaceuticals under Progression in China

5.3.1 Antibodies

5.3.2 Long-acting Proteins

5.3.3 Gene Therapy Products

5.3.4 New vaccines

5.4 Challenges Faced by Biopharmaceuticals in China

5.4.1 Overproduction of Simpler Drugs is Leading to Over-Competition in Domestic Markets

5.4.2 Weak Strategic Planning and Management Skills

5.4.3 Expression Deficit to Limit the Development and Industrialization of Biopharmaceuticals

5.5 Propositions for the Advancement of Biopharmaceuticals in China

5.5.1 Internationalize the Regulatory System to Eliminate Deficiencies for Biopharmaceutical Products

5.5.2 Breakthrough Innovation is Critical for the Success of Biopharmaceuticals

5.5.3 Set up Industrial Standards and Fortify Manufacturing Capacity

5.5.4 Augment Communication Between Researchers and Clinicians for Developing Biopharmaceuticals

5.6 Contract Manufacturing Scenario in China

5.7 Competitive Landscape

5.7.1 Hualan Biological Engineering Co., Ltd.

5.7.2 Shanghai Kehua Biological Engineering Co., Ltd.

5.7.3 Beijing Tiantan Biological Products Co., Ltd.

5.7.4 Beijing SL Pharmaceutical Co., Ltd.

5.7.5 Shanghai RAAS Blood Products Co., Ltd.

6 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical Manufacturing in South Korea

6.1 South Korean Biopharmaceutical Industry

6.2 Market Size for South Korean Biopharmaceuticals

6.3 Evolution of the Biopharmaceutical Industry in South Korea

6.4 Korean Free Trade Agreement with the US

6.5 Drivers Affecting Biopharmaceuticals in South Korea

6.5.1 Korea/US Free Trade Agreement

6.5.2 Punishment Systems and Price Reduction

6.5.3 Government Initiatives for the Development of the Biopharmaceutical Industry

6.6 Major R&D Achievements in South Korea

6.7 South Korea’s Strategic Advantage over India and China

6.8 Competitive Landscape

6.8.1 Celltrion

6.8.2 LG Life Sciences

6.8.3 Hanwha Chemical

6.8.4 ISU Abxis

6.8.5 Green Cross

7 Biopharmaceutical Manufacturing in India, China and South Korea - Appendix

7.1 Market Definitions

7.2 Abbreviations

7.3 Bibliography

7.4 Research Methodology

7.4.1 Coverage

7.4.2 Secondary Research

7.4.3 Primary Research

7.4.4 Expert Panel Validation

7.5 Contact Us

7.6 Disclaimer

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards